Dr. Notaristefani, PhD, will be replaced by Eric Drapé, PharmD.
In 2017, Teva had $35 billion in debt. Under Dr. Notaristefani’s leadership, Teva reduced its debt by $3 billion. The debt reduction was mainly achieved by cutting 14,000 jobs and consolidating its seven U.S. sites into one location.
Dr. Drapé joined Teva in 2014 and most recently served as its chief quality officer.
Before joining Teva, Dr. Drapé was the executive vice president of technical operations at Ipsen Pharma and served in several leadership positions at Novo Nordisk.
Dr. Drapé will be based out of Teva’s global headquarters in Israel.
Read the full news release here.
More articles on pharmacy:
Following CVS, Walgreens and Rite Aid pull Zantac from shelves
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
